ES2104424T3 - Compuestos de isoxazolina como agentes antiinflamatorios. - Google Patents

Compuestos de isoxazolina como agentes antiinflamatorios.

Info

Publication number
ES2104424T3
ES2104424T3 ES94929001T ES94929001T ES2104424T3 ES 2104424 T3 ES2104424 T3 ES 2104424T3 ES 94929001 T ES94929001 T ES 94929001T ES 94929001 T ES94929001 T ES 94929001T ES 2104424 T3 ES2104424 T3 ES 2104424T3
Authority
ES
Spain
Prior art keywords
isoxazoline compounds
inflammatory agents
ffdiv
dermatitis
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929001T
Other languages
English (en)
Inventor
Edward F Kleinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2104424T3 publication Critical patent/ES2104424T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE ISOXAZOLINA QUE SON IHIBIDORES SELECTIVOS DE FOSFODIESTERASA TIPO IV (FFDIV). LOS NUEVOS COMPUESTOS DE ISOXAZOLINA SON UTILES PARA INHIBIR FFDIV Y EN EL TRATAMIENTO DE SIDA, ASMA, ARTRITIS, BRONQUITIS, ENFERMEDADES CRONICAS DE OBSTRUCCION PULMONAR, PSORIASIS, RINITIS ALERGICA, DERMATITIS, SHOCK, DERMATITIS ATOPICA, ARTRITIS REUMATOIDE Y OSTEOARTRITIS. ESTA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS UTILES PARA LO MISMO.
ES94929001T 1993-11-26 1994-10-26 Compuestos de isoxazolina como agentes antiinflamatorios. Expired - Lifetime ES2104424T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15724893A 1993-11-26 1993-11-26
US26208694A 1994-06-17 1994-06-17

Publications (1)

Publication Number Publication Date
ES2104424T3 true ES2104424T3 (es) 1997-10-01

Family

ID=26853945

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929001T Expired - Lifetime ES2104424T3 (es) 1993-11-26 1994-10-26 Compuestos de isoxazolina como agentes antiinflamatorios.

Country Status (24)

Country Link
US (1) US5716967A (es)
EP (1) EP0730588B1 (es)
JP (1) JP2802547B2 (es)
KR (1) KR0182324B1 (es)
CN (1) CN1046274C (es)
AT (1) ATE154932T1 (es)
AU (1) AU687452B2 (es)
BR (1) BR9408174A (es)
CA (1) CA2176255C (es)
CO (1) CO4180606A1 (es)
CZ (1) CZ283564B6 (es)
DE (1) DE69404044T2 (es)
DK (1) DK0730588T3 (es)
EG (1) EG20693A (es)
ES (1) ES2104424T3 (es)
FI (1) FI945557L (es)
GR (1) GR3024133T3 (es)
HU (1) HUT76784A (es)
IL (1) IL111670A (es)
NO (1) NO962127D0 (es)
NZ (1) NZ274244A (es)
PE (1) PE33495A1 (es)
PL (1) PL314605A1 (es)
WO (1) WO1995014681A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU684887B2 (en) * 1994-03-09 1998-01-08 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
JP4195561B2 (ja) * 1999-09-17 2008-12-10 エルジー ケム インヴェストメント リミティッド カスパーゼインヒビター
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO2002100332A2 (en) 2001-06-08 2002-12-19 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
AU2003301903A1 (en) * 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
BRPI0507818A (pt) * 2004-03-26 2007-07-10 Cytokine Pharmasciences Inc composto e métodos de inibição
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
WO2006097273A1 (en) * 2005-03-15 2006-09-21 Ganial Immunotherapeutics Inc. Compounds having immunomodulator activity
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
ES2351161T3 (es) * 2005-05-03 2011-02-01 Ranbaxy Laboratories Limited Inhibidores de la fosfodiesterasa a base de azol.
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
DK2691379T3 (en) 2011-03-31 2017-02-13 Bayer Ip Gmbh HERBICID AND FUNGICID ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLIN-5-THIOAMIDES
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150064221A1 (en) 2012-04-17 2015-03-05 Niranjan Y. Sardesai Compounds having immunomudulator activity
BR112015006573B1 (pt) * 2012-09-25 2020-11-03 Bayer Cropscience Ag derivados de 3-fenilisoxazolina, compoisições herbicidas, seus usos, e método para controle de plantas indesejáveis
ES2636596T3 (es) * 2012-11-20 2017-10-06 Biogen Ma Inc. Agentes moduladores de S1P y/o ATX
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CN103381157A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone B在治疗慢性阻塞性肺疾病的药物中的应用
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
CN106573924B (zh) * 2014-04-22 2019-06-25 诺华股份有限公司 作为LpxC抑制剂的异噁唑啉异羟肟酸衍生物
EA202090018A1 (ru) 2017-06-13 2020-05-26 Байер Акциенгезельшафт Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды тетрагидро- и дигидрофурановых карбоксамидов
SI3638665T1 (sl) 2017-06-13 2021-11-30 Bayer Aktiengesellschaft Herbicidni 3-fenilizoksazolin-5-karboksamidi tetrahidro in dihidrofuran karboksilnih kislin in estrov
EP3668845B1 (de) 2017-08-17 2024-06-26 Bayer Aktiengesellschaft Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern
EP3743411B1 (de) 2018-01-25 2022-12-21 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von cyclopentenylcarbonsäurederivaten
CA3133025A1 (en) 2019-03-12 2020-09-17 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
JPS62103070A (ja) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US4731382A (en) * 1986-12-29 1988-03-15 Bristol-Myers Company Lipoxygenase inhibitory phenylalkanohydroxamic acids
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
IL92915A0 (en) * 1989-01-05 1990-09-17 Ciba Geigy Ag Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
DE3939010A1 (de) * 1989-11-25 1991-05-29 Hoechst Ag Isoxazoline, verfahren zu ihrer herstellung und ihre verwendung als pflanzenschuetzende mittel
JP2787602B2 (ja) * 1990-01-24 1998-08-20 大鵬薬品工業株式会社 イソキサゾリン誘導体
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5140047A (en) * 1991-05-03 1992-08-18 Smithkline Beecham Corporation Lipoxygenase inhibitors
GB9215921D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
WO1994018158A1 (en) * 1993-02-15 1994-08-18 Pfizer Inc. Spiroalkylhydroxyureas for use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
CN1136314A (zh) 1996-11-20
JPH09500147A (ja) 1997-01-07
HUT76784A (en) 1997-11-28
KR0182324B1 (ko) 1999-05-01
PL314605A1 (en) 1996-09-16
GR3024133T3 (en) 1997-10-31
IL111670A (en) 1998-08-16
EG20693A (en) 1999-11-30
FI945557A7 (fi) 1995-05-27
EP0730588B1 (en) 1997-07-02
WO1995014681A1 (en) 1995-06-01
FI945557A0 (fi) 1994-11-25
BR9408174A (pt) 1997-05-27
CO4180606A1 (es) 1995-06-07
NO962127L (no) 1996-05-24
CA2176255A1 (en) 1995-06-01
ATE154932T1 (de) 1997-07-15
FI945557L (fi) 1995-05-27
HU9601412D0 (en) 1996-07-29
EP0730588A1 (en) 1996-09-11
DE69404044D1 (de) 1997-08-07
JP2802547B2 (ja) 1998-09-24
US5716967A (en) 1998-02-10
CA2176255C (en) 1999-02-23
NO962127D0 (no) 1996-05-24
KR960705795A (ko) 1996-11-08
NZ274244A (en) 1997-09-22
DK0730588T3 (da) 1997-12-08
DE69404044T2 (de) 1997-10-16
AU7821894A (en) 1995-06-13
IL111670A0 (en) 1995-01-24
AU687452B2 (en) 1998-02-26
CZ283564B6 (cs) 1998-05-13
CN1046274C (zh) 1999-11-10
CZ151096A3 (en) 1997-01-15
PE33495A1 (es) 1995-10-27

Similar Documents

Publication Publication Date Title
ES2139754T3 (es) 3-fenil-2-isoxazolinas como agentes antiinflamatorios.
CO4180606A1 (es) Compuestos de isoxazolina como agentes antiinflamatorios
ES2192192T3 (es) Dieteres de catecol como inhibidores selectivos de pde iv.
ES2154683T3 (es) Indoles sustituidos como inhibidores de fosfodiesterasa de tipo iv.
JOP20210179A1 (ar) مثبطات إيميدازو[1، 2-b] بيريدازين IL-17A
MX9405132A (es) Tetrahidro pirazolopiridinas biciclicas.
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
CR8254A (es) [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
MX9504422A (es) Tetrahidropirazolopiridinas biciclicas.
ECSP045476A (es) Tiazolidinonas, su preparación y su uso como medicamentos
DK0626853T3 (da) Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
PA8543301A1 (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2 -ona como antagonistas ii mglur2
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
DOP2002000473A (es) Alquinos como inhibidores de metaloproteinasa de matriz
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
UY27259A1 (es) Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2
ES2058306T3 (es) Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas.
BR0212661A (pt) Compostos de pirazolil benzenossulfamida substituìdos para o tratamento de inflamação
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730588

Country of ref document: ES